Olverembatinib (HQP1351) Overcomes Ponatinib And/or Asciminib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (ph+ ALL)
Clinical Lymphoma Myeloma and Leukemia（2024）
Key words
CML,Ph plus ALL,T315I mutation,TKI,phase 2
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined